Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Peerlinck, K' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 58 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Kulkarni, R; Aledort, LM; Berntorp, E; Brackman, HH; Brown, D; Cohen, AR; Ewing, NP; Gringeri, A; Gruppo, R; Hoots, K; Leissenger, C; Peerlinck, K; Poon, MC; Wong, WY
      Therapeutic choices for patients with hemophilia and high-titer inhibitors

      AMERICAN JOURNAL OF HEMATOLOGY
    2. Peerlinck, K; Vermylen, J
      Drugs affecting blood coagulation, fibrinolysis, and hemostasis

      SIDE EFFECTS OF DRUGS ANNUAL 23
    3. Jacquemin, M; Lavend'homme, R; Benhida, A; Vanzieleghem, B; d'Oiron, R; Lavergne, JM; Brackmann, HH; Schwaab, R; VandenDriessche, T; Chuah, MKL; Hoylaerts, M; Gilles, JGG; Peerlinck, K; Vermylen, J; Saint-Remy, JMR
      A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIIIC1 domain reduce factor VIII binding to von Willebrand factor

      BLOOD
    4. Neerman-Arbez, M; de Moerloose, P; Bridel, C; Honsberger, A; Schonborner, A; Rossier, C; Peerlinck, K; Claeyssens, S; Di Michele, D; d'Oiron, R; Dreyfus, M; Laubriat-Bianchin, M; Dieval, J; Antonarakis, SE; Morris, MA
      Mutations in the fibrinogen A alpha gene account for the majority of casesof congenital afibrinogenemia

      BLOOD
    5. Jacquemin, M; Benhida, A; Peerlinck, K; Desqueper, B; Elst, LV; Lavend'homme, R; d'Oiron, R; Schwaab, R; Bakkus, M; Thielemans, K; Gilles, JG; Vermylen, J; Saint-Remy, JM
      A human antibody directed to the factor VIIIC1 domain inhibits factor VIIIcofactor activity and binding to von Willebrand factor

      BLOOD
    6. Peerlinck, K; Vermylen, J
      Acute myocardial infarction following administration of recombinant activated factor VII (Novo seven) in a patient with haemophilia A and inhibitor

      THROMBOSIS AND HAEMOSTASIS
    7. Gilles, JGG; Lavend'homme, R; Peerlinck, K; Jacquemin, MG; Hoylaerts, M; Jorieux, S; Mazurier, C; Vermylen, J; Saint-Remy, JMR
      Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes

      THROMBOSIS AND HAEMOSTASIS
    8. Vandenberghe, P; Peerlinck, K
      Transfusion medicine

      NEW ENGLAND JOURNAL OF MEDICINE
    9. Bellemans, J; Stockx, L; Peerlinck, K; Vermylen, J; Lacroix, H; Suy, R
      Arterial occlusion and thrombus aspiration after total knee arthroplasty

      CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
    10. Peerlinck, K; Jacquemin, MG; Arnout, J; Hoylaerts, MF; Gilles, JGG; Lavend'homme, R; Johnson, KM; Freson, K; Scandella, D; Saint-Remy, JMR; Vermylen, J
      Antifactor VIII antibody inhibiting allogeneic but not antologous factor VIII in patients with mild hemophilia A

      BLOOD
    11. FRESON K; PEERLINCK K; AGUIRRE T; ARNOUT J; VERMYLEN J; CASSIMAN JJ; MATTHIJS G
      FLUORESCENT CHEMICAL CLEAVAGE OF MISMATCHES FOR EFFICIENT SCREENING OF THE FACTOR-VIII GENE

      Human mutation
    12. SCHULMAN S; DOIRON R; MARTINOWITZ U; PASI J; BRIQUEL ME; MAUSERBUNSCHOTEN E; MORFINI M; RITCHIE B; GOUDEMAND J; LLOYD J; MCPHERSON J; NEGRIER C; PEERLINCK K; PETRINI P; TUSELL J
      EXPERIENCES WITH CONTINUOUS-INFUSION OF RECOMBINANT ACTIVATED FACTOR-VII

      Blood coagulation & fibrinolysis
    13. Deckmyn, H; Vanhoorelbeke, K; Peerlinck, K
      Inhibitory and activating human antiplatelet antibodies

      BAILLIERES CLINICAL HAEMATOLOGY
    14. Vermylen, J; Peerlinck, K
      Optimal care of inhibitor patients during surgery

      EUROPEAN JOURNAL OF HAEMATOLOGY
    15. Peerlinck, K; Vermylen, J
      Drugs affecting blood coagulation, fibrinolysis, and hemostasis

      SIDE EFFECTS OF DRUGS ANNUAL 21
    16. JOCHMANS K; LISSENS W; SENECA S; CAPEL P; CHATELAIN B; MEEUS P; OSSELAER JC; PEERLINCK K; SEGHERS J; SLACMEULDER M; STIBBE J; VANDELOO J; VERMYLEN J; LIEBAERS I; DEWAELE M
      THE MOLECULAR-BASIS OF ANTITHROMBIN DEFICIENCY IN BELGIAN AND DUTCH FAMILIES

      Thrombosis and haemostasis
    17. SHENG L; SOUMILLION A; PEERLINCK K; VERSLYPE C; SCHELSTRAETE R; GYSELINCK F; EMONDS MP; HESS G; VERMYLEN J; DESMYTER J; YAP SH
      ANTI-HEPATITIS-G E2 ANTIBODY DETECTION AND ITS RELATION TO SERUM HGV-RNA IN PATIENTS WITH CLOTTING DISORDERS - HIGH PREVALENCE OF HGV INFECTION AND SPONTANEOUS REMISSION

      Thrombosis and haemostasis
    18. SAWAMOTO Y; PRESCOTT R; ZHONG DG; SAENKO EL; MAUSERBUNSCHOTEN E; PEERLINCK K; VANDENBERG M; SCANDELLA D
      DOMINANT C2 DOMAIN EPITOPE SPECIFICITY OF INHIBITOR ANTIBODIES ELICITED BY A HEAT PASTEURIZED PRODUCT, FACTOR-VIII CPS-P, IN PREVIOUSLY TREATED HEMOPHILIA-A PATIENTS WITHOUT INHIBITORS

      Thrombosis and haemostasis
    19. Mauser-Bunschoten, EP; de Goede-Bolder, A; Wielenga, JJ; Levi, M; Peerlinck, K
      Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors - Experience in the Netherlands and Belgium.

      NETHERLANDS JOURNAL OF MEDICINE
    20. JACQUEMIN MG; DESQUEPER BG; BENHIDA A; VANDERELST L; HOYLAERTS MF; BAKKUS M; THIELEMANS K; ARNOUT J; PEERLINCK K; GILLES JGG; VERMYLEN J; SAINTREMY JMR
      MECHANISM AND KINETICS OF FACTOR-VIII INACTIVATION - STUDY WITH AN IGG4 MONOCLONAL-ANTIBODY DERIVED FROM A HEMOPHILIA-A PATIENT WITH INHIBITOR

      Blood
    21. SHENG L; SOUMILLION A; PEERLINCK K; VERSLYPE C; LIN L; VANPELT J; HESS G; VERMYLEN J; YAP SH
      HEPATITIS-G VIRAL-RNA IN SERUM AND IN PERIPHERAL-BLOOD MONONUCLEAR-CELLS AND ITS RELATION TO HCV-RNA IN PATIENTS WITH CLOTTING DISORDERS

      Thrombosis and haemostasis
    22. GILLES JGG; PEERLINCK K; ARNOUT J; VERMYLEN J; SAINTREMY JMR
      RESTRICTED EPITOPE SPECIFICITY OF ANTI-FVIII ANTIBODIES THAT APPEAREDDURING A RECENT OUTBREAK OF INHIBITORS

      Thrombosis and haemostasis
    23. PEERLINCK K; ARNOUT J; DIGIAMBATTISTA M; GILLES JG; LAUB R; JACQUEMIN M; SAINTREMY JMR; VERMYLEN J
      FACTOR-VIII INHIBITORS IN PREVIOUSLY TREATED HEMOPHILIA-A PATIENTS WITH A DOUBLE VIRUS-INACTIVATED PLASMA-DERIVED FACTOR-VIII CONCENTRATE

      Thrombosis and haemostasis
    24. JACQUEMIN H; DESQUEPER B; GILLES J; ARNOUT J; PEERLINCK K; VERMYLEN J; SAINTREMY JM
      PRODUCTION OF HUMAN MONOCLONAL ANTI-FVIII IGG ANTIBODIES BY IMMORTALIZATION OF MEMORY B-LYMPHOCYTES FROM HEMOPHILIA-A PATIENTS WITH INHIBITORS

      Thrombosis and haemostasis
    25. JOCHMANS K; LISSENS W; PEERLINCK K; SEGHERS J; STIBBE J; VANDELOO J; DEWAELE M; LIEBAERS I
      IDENTIFICATION OF 5 NOVEL MUTATIONS RESPONSIBLE FOR TYPE-1 ANTITHROMBIN DEFICIENCY

      Thrombosis and haemostasis
    26. PEERLINCK K; SHENG L; SOUMILLION A; VERSLYPE C; VANPELT J; HESS G; YAP SH; VERMYLEN J
      HEPATITIS-G VIRAL-RNA IN SERUM AND IN PERIPHERAL-BLOOD MONONUCLEAR-CELLS IN PATIENTS WITH CLOTTING DISORDERS

      Thrombosis and haemostasis
    27. SHENG L; SOUMILLION A; PEERLINCK K; VERSLYPE C; VANPELT J; SCHELSTRAETE R; EMONDS MP; HESS G; DESMYTER J; VERMYLEN J; YAP SH
      DETECTION OF HGV-RNA IN PERIPHERAL-BLOOD MONONUCLEAR-CELLS (PBMC) ANDIN SERUM OF ANTI-HGV-E2 POSITIVE HEMOPHILIACS

      Hepatology
    28. GILLES JGG; LAVENDHOMME R; JACQUEMIN MG; PEERLINCK K; VERMYLEN J; SAINTREMY JMR
      ANTI-FACTOR-VIII INHIBITORY ANTIBODIES BELONGING TO THE IGA1 ISOTYPE IN A MILD HEMOPHILIA-A PATIENT

      Blood
    29. JACQUEMIN MG; DESQUEPER B; LAVENDHOMME R; PEERLINCK K; GILLES JG; VERMYLEN J; SAINTREMY JMR
      A HUMAN MONOCLONAL-ANTIBODY FROM A MILD HEMOPHILIA-A PATIENT NEUTRALIZING ALLOGENEIC BUT NOT AUTOLOGOUS FACTOR-VIII

      Blood
    30. PEERLINCK K; ARNOUT J; JACQUEMIN MG; GILLES JG; LAVENDHOMME R; FRESON K; SAINTREMY JMR; VERMYLEN J
      A PATIENT WITH MILD HEMOPHILIA-A AND A HIGH-TITER ANTIFACTOR-VIII ANTIBODY AGAINST EXOGENOUS FACTOR-VIII ONLY - CLINICAL-FEATURES, SURGICAL-MANAGEMENT AND PARTIAL CHARACTERIZATION OF THE INHIBITOR

      Blood
    31. JACQUEMIN MG; DESQUEPER BG; BENHIDA A; VANDERELST L; HOYLAERTS MF; BAKKUS M; THIELEMANS K; ARNOUT J; PEERLINCK K; GILLES JGG; VERMYLEN J; SAINTREMY JMR
      MOLECULAR CHARACTERIZATION OF A FACTOR-VIII SPECIFIC IGG4 MONOCLONAL-ANTIBODY DERIVED FROM A HEMOPHILIA-A PATIENT WITH INHIBITOR

      Blood
    32. GOUBAU P; REYNDERS M; BEUSELINCK K; NEVENS F; PEERLINCK K; DESMYTER J
      CONFIRMATORY STRATEGY OF HEPATITIS-C SEROLOGY BASED ON 2 SCREENING ASSAYS IN A DIAGNOSTIC SETTING

      Acta Clinica Belgica
    33. SHENG L; SOUMILLION A; PEERLINCK K; VERSLYPE C; VANPELT J; HESS G; VERMYLEN J; YAP SH
      HEPATITIS-G VIRUS IN PERIPHERAL-BLOOD MONONUCLEAR-CELLS IN HEMOPHILIACS

      Hepatology
    34. SHENG L; SOUMILLION A; PEERLINCK K; VERSLYPE C; VANPELT J; HESS G; VERMYLEN J; YAP SH
      HEPATITIS-G VIRUS-INFECTION IN BELGIAN HEMOPHILIACS

      Hepatology
    35. PEERLINCK K; MATTHIJS G; CASSIMAN JJ; VERMYLEN J
      INTRON 22 INVERSIONS OF THE FACTOR-VIII GENE IN BELGIAN PATIENTS WITHSEVERE HEMOPHILIA-A - PREVALENCE AND LACK OF RELATION WITH INHIBITOR STATUS

      Thrombosis and haemostasis
    36. PEERLINCK K; GOUBAU P; REYBROUCK R; DESMYTER J; VERMYLEN J
      PARVOVIRUS B19 ANTIBODIES IN PATIENTS WITH HEMOPHILIA-A

      Thrombosis and haemostasis
    37. HOYLAERTS MF; NUYTS K; PEERLINCK K; DECKMYN H; VERMYLEN J
      PROMOTION OF FINDING OF VON-WILLEBRAND-FACTOR TO PLATELET GLYCOPROTEIN IB BY DIMERS OF RISTOCETIN

      Biochemical journal
    38. SHENG L; WILLEMS M; PEERLINCK K; VERMYLEN J; YAP SH
      HEPATITIS-C VIRUS GENOTYPES IN BELGIAN HEMOPHILIACS

      Journal of medical virology
    39. VERMYLEN J; PEERLINCK K
      FATAL COMPLICATION OF DESMOPRESSIN

      Lancet
    40. ANTONARAKIS SE; ROSSITER JP; YOUNG M; HORST J; DEMOERLOOSE P; SOMMER SS; KETTERLING RP; KAZAZIAN HH; NEGRIER C; VINCIGUERRA C; GITSCHIER J; GOOSSENS M; GIRODON E; GHANEM N; PLASSA F; LAVERGNE JM; VIDAUD M; COSTA JM; LAURIAN Y; LIN SW; LIN SR; SHEN MC; LILLICRAP D; TAYLOR SAM; WINDSOR S; VALLEIX SV; NAFA K; SULTAN Y; DELPECH M; VNENCAKJONES CL; PHILLIPS JA; LJUNG RCR; KOUMBARELIS E; GIALERAKI A; MANDALAKI T; JENKINS PV; COLLINS PW; PASI KJ; GOODEVE A; PEAKE I; PRESTON FE; SCHWARTZ M; SCHEIBEL E; INGERSLEV J; COOPER DN; MILLAR DS; KAKKAR VV; GIANNELLI F; NAYLOR JA; TIZZANO EF; BAIGET M; DOMENECH M; ALTISENT C; TUSELL J; BENEYTO M; LORENZO JI; GAUCHER C; MAZURIER C; PEERLINCK K; MATTHIJS G; CASSIMAN JJ; VERMYLEN J; MORI PG; ACQUILA M; CAPRINO D; INABA H
      FACTOR-VIII GENE INVERSIONS IN SEVERE HEMOPHILIA-A - RESULTS OF AN INTERNATIONAL CONSORTIUM STUDY

      Blood
    41. BRIET E; ROSENDAAL FR; KREUZ W; RASI V; PEERLINCK K; VERMYLEN J; LJUNG R; ROCINO A; ADDIEGO J; LORENZO JI; PABINGER I
      HIGH-TITER INHIBITORS IN SEVERE HEMOPHILIA-A - A METAANALYSIS BASED ON 8 LONG-TERM FOLLOW-UP-STUDIES CONCERNING INHIBITORS ASSOCIATED WITH CRUDE OR INTERMEDIATE PURITY FACTOR-VIII PRODUCTS

      Thrombosis and haemostasis
    42. WILLEMS M; PEERLINCK K; MOSHAGE H; DELEU I; VANDENEYNDE C; VERMYLEN J; YAP SH
      HEPATITIS-C VIRUS-RNAS IN PLASMA AND IN PERIPHERAL-BLOOD MONONUCLEAR-CELLS OF HEMOPHILIACS WITH CHRONIC HEPATITIS-C - EVIDENCE FOR VIRAL REPLICATION IN PERIPHERAL-BLOOD MONONUCLEAR-CELLS

      Journal of medical virology
    43. VERMYLEN J; PEERLINCK K
      REVIEW OF THE HEPATITIS-A EPIDEMICS IN HEMOPHILIACS IN EUROPE

      Vox sanguinis
    44. PEERLINCK K; GOUBAU P; COPPENS G; DESMYTER J; VERMYLEN J
      IS THE APPARENT OUTBREAK OF HEPATITIS-A IN BELGIAN HEMOPHILIACS DUE TO A LASS OF PREVIOUS PASSIVE-IMMUNITY

      Vox sanguinis
    45. MCOMISH F; YAP PL; HART H; PEERLINCK K; BURNS SM; SIMMONDS P
      FAILURE TO DETECT HEPATITIS-A VIRUS-RNA IN FACTOR-VIII CONCENTRATES USING THE POLYMERASE CHAIN-REACTION - RESULTS OF A PRELIMINARY-STUDY

      Vox sanguinis
    46. BARRETT JS; MURPHY G; PEERLINCK K; LEPELEIRE ID; GOULD RJ; PANEBIANCO D; HAND E; DECKMYN H; VERMYLEN J; ARNOUT J
      PHARMACOKINETICS AND PHARMACODYNAMICS OF MK-383, A SELECTIVE NONPEPTIDE PLATELET GLYCOPROTEIN-IIB IIIA RECEPTOR ANTAGONIST, IN HEALTHY-MEN/

      Clinical pharmacology and therapeutics
    47. PEERLINCK K; WILLEMS M; SHENG L; NEVENS F; FEVERY J; YAP SH; VERMYLEN J
      RAPID CLEARANCE OF HEPATITIS-C VIRUS-RNA IN PERIPHERAL-BLOOD MONONUCLEAR-CELLS OF PATIENTS WITH CLOTTING DISORDERS AND CHRONIC HEPATITIS-C TREATED WITH ALPHA-2B INTERFERON IS NOT A PREDICTOR FOR SUSTAINED RESPONSE TO TREATMENT

      British Journal of Haematology
    48. JOCHMANS K; LISSENS W; YIN T; MICHIELS JJ; VANDERLUIT L; PEERLINCK K; DEWAELE M; LIEBAERS I
      MOLECULAR-BASIS FOR TYPE-1 ANTITHROMBIN DEFICIENCY - IDENTIFICATION OF 2 NOVEL POINT MUTATIONS AND EVIDENCE FOR A DE-NOVO SPLICE-SITE MUTATION

      Blood
    49. GILLES JGG; ARNOUT J; PEERLINCK K; VERMYLEN J; SAINTREMY JMR
      A SUDDEN OUTBREAK OF INHIBITORS DURING TREATMENT WITH A PARTICULAR PASTEURIZED FACTOR-VIII CONCENTRATE (FVIII-CPS-P) - CHARACTERIZATION OF SPECIFIC ANTIBODIES

      Thrombosis and haemostasis
    50. PEERLINCK K; ARNOUT J; DELEPELEIRE I; GOLDBERG M; FITZPATRICK V; VERMYLEN J
      COMBINED EFFECT OF ASPIRIN AND MK 383 (L-700,462), A SELECTIVE GPIIB IIIA ANTAGONIST, IN HEALTHY-VOLUNTEERS/

      Thrombosis and haemostasis
    51. PEERLINCK K; WILLEMS M; SHENG L; NEVENS F; YAP SH; FEVERY J; VERMYLEN J
      EFFECT OF TREATMENT WITH INTERFERON ALFA-2B (IFN) ON SERUM ALANINE AMINO TRANSFERASE (ALT) AND ON HEPATITIS-C VIRUS (HCV)-RNA IN PLASMA ANDPERIPHERAL-BLOOD MONONUCLEAR-CELLS (PBMC) IN PATIENTS WITH HEMOPHILIAAND CHRONIC HCV INFECTION

      Thrombosis and haemostasis
    52. TORNAI I; ARNOUT J; DECKMYN H; PEERLINCK K; BODA Z; VERMYLEN J
      A MONOCLONAL-ANTIBODY INDUCES CHANGES IN THE FUNCTION OF NORMAL VON-WILLEBRAND-FACTOR (VWF), THAT THEN BEHAVES LIKE TYPE-IIB

      Thrombosis and haemostasis
    53. REIJNEN MJ; PEERLINCK K; MAASDAM D; BERTINA RM; REITSMA PH
      HEMOPHILIA-B LEYDEN - SUBSTITUTION OF T FOR G AT POSITION -21 RESULTSIN A DISRUPTION OF A HNF-4 BINDING-SITE IN THE FACTOR-IX PROMOTER

      Thrombosis and haemostasis
    54. EIKENBOOM JCJ; REITSMA PH; PEERLINCK K; BRIET E
      RECESSIVE INHERITANCE OF VON-WILLEBRAND DISEASE TYPE-I - COMPOUND HETEROZYGOSITY OF SYMPTOMATIC INDEX CASES

      Thrombosis and haemostasis
    55. PEERLINCK K; VERMYLEN J; ROSENDAAL F; BRIET E
      FACTOR-VIII INHIBITOR

      Lancet
    56. PEERLINCK K; DELEPELEIRE I; GOLDBERG M; FARRELL D; BARRETT J; HAND E; PANEBIANCO D; DECKMYN H; VERMYLEN J; ARNOUT J
      MK-383 (L-700,462), A SELECTIVE NONPEPTIDE PLATELET GLYCOPROTEIN-IIB IIIA ANTAGONIST, IS ACTIVE IN MAN/

      Circulation
    57. REIJNEN MJ; PEERLINCK K; MAASDAM D; BERTINA RM; REITSMA PH
      HEMOPHILIA-B LEYDEN - SUBSTITUTION OF THYMINE FOR GUANINE AT POSITION-(-21) - RESULTS IN A DISRUPTION OF A HEPATOCYTE NUCLEAR FACTOR-IV BINDING-SITE IN THE FACTOR-IX PROMOTER

      Blood
    58. PEERLINCK K; ROSENDAAL FR; VERMYLEN J
      INCIDENCE OF INHIBITOR DEVELOPMENT IN A GROUP OF YOUNG HEMOPHILIA-A PATIENTS TREATED EXCLUSIVELY WITH LYOPHILIZED CRYOPRECIPITATE

      Blood


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/10/20 alle ore 13:13:28